Background: Thyrotoxicosis has multiple etiologies, manifestations, and potential therapies.
Appropriate treatment requires an accurate diagnosis and is influenced by coexisting …

Tyrosine kinase inhibitors (TKIs) are emerging as potentially effective options in the
treatment of cancer, acting on the pathways involved in growth, avoidance of apoptosis …

The enormous success in the therapeutic area of oncology has allowed achieving a number
of long-term survival patients unthinkable until a few decades ago. The number of cancer …

Introduction: Sunitinib is an oral oxindol derivative and a potent inhibitor of vascular
endothelial growth factor receptor and platelet-derived growth factor receptor and a …

Thyrotoxicosis is a clinical disorder caused by an caused by the effect of excess of thyroid
hormone in tissues, whereas hyperthyroidism refers to an increased thyroid hormone …

Abstract Objective Tyrosine-kinase inhibitors (TKIs) are chemotherapeutic agents associated
with increased thyroid-hormone requirements and altered deiodinase activity. We present …

Purpose: Along with increased cancer incidence, there is also an increased use of targeted
cancer therapy. One of the most potent classes of targeted therapy drugs are tyrosine kinase …

Thyrotoxicosis is a term for excess thyroid hormone action. Hyperthyroidism is when thyroid
is producing and releasing excess hormones. The most common cause is Graves' …

Abstract The Side Effects of Drugs Annuals is a series of volumes in which the adverse
effects of drugs and adverse reactions to them are surveyed. The series supplements the …

Pazopanib is an oral multi-targeted tyrosine kinase inhibitor and has been approved for
metastatic renal cell carcinoma and advanced soft tissue sarcoma. To the best of our …